Pharmaceutical Overview of Sumitop
Sumitop 50 mg is a pharmaceutical preparation containing sumatriptan succinate manufactured by Centurion Laboratories. Sumatriptan is a triptan-class compound that functions as a selective 5-hydroxytryptamine 1B and 1D (5-HT1B/1D) receptor agonist. This compound was originally developed for acute migraine treatment and belongs to a class of molecules extensively studied for their effects on cranial vascular systems and trigeminal nerve pathways. Research applications focus on investigating serotonin receptor pharmacology, vascular biology, and neurological pathway modulation in controlled laboratory environments.
Research Applications and Mechanisms
In laboratory research contexts, sumatriptan serves as a valuable tool compound for examining 5-HT1B/1D receptor function and downstream signaling cascades. Researchers investigate its effects on cranial blood vessel constriction, trigeminal nerve activity modulation, and central nervous system serotonin pathways. The compound’s selective receptor binding profile makes it particularly useful for studying migraine pathophysiology models and developing understanding of triptan mechanism of action. Scientists at Stroid UK Shop can examine how sumatriptan influences vasoconstriction, neurogenic inflammation, and pain transmission pathways. Research applications extend to studying drug metabolism via monoamine oxidase A pathways and investigating potential interactions with other pharmaceutical agents. The sumatriptan research category provides additional compounds for comparative receptor binding studies. Researchers may also explore its utility alongside selective androgen receptor modulators or peptide compounds in multi-pathway investigations.
Technical Specifications
| Active Ingredient | Sumatriptan Succinate |
|---|---|
| Strength | 50 mg per tablet |
| Manufacturer | Centurion Laboratories |
| CAS Number | 103628-48-4 (succinate salt) |
| Molecular Formula | C₁₄H₂₁N₃O₂S·C₄H₆O₄ |
| Molecular Weight | 413.49 g/mol |
| Storage | Room temperature, dry conditions |
| Form | Oral tablets |
Research Compliance Information
Sumitop 50 mg tablets are supplied strictly for in-vitro research and analytical purposes only. This pharmaceutical preparation is not intended for human consumption or therapeutic use. Researchers must ensure appropriate laboratory protocols, safety measures, and regulatory compliance when handling this compound. All studies should be conducted by qualified personnel in appropriate research facilities with proper ventilation and safety equipment. This product is intended solely for investigating sumatriptan’s pharmacological properties, receptor binding characteristics, and mechanisms of action in controlled research environments.
